Back to top
more

Conatus Pharmaceuticals Inc. (CNAT)

(Delayed Data from NSDQ)

$0.90 USD

0.90
746,677

+0.05 (5.88%)

Updated May 3, 2019 03:59 PM ET

After-Market: $0.90 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

4 items in cart

View Cart/Checkout

Histogen Inc. [CNAT]

Reports for Purchase

Showing records 181 - 200 ( 226 total )

Company: Histogen Inc.

Industry: Medical - Products

Record: 181

01/05/2016

Daily Note

Pages: 4

Another [Significant] Brick in the Wall

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 182

12/28/2015

Company Report

Pages: 7

Price: 24.95

Company: Histogen Inc.

Industry: Medical - Products

Record: 183

11/24/2015

Company Report

Pages: 7

Price: 24.95

Company: Histogen Inc.

Industry: Medical - Products

Record: 184

11/09/2015

Company Report

Pages: 7

Conatus Unveils ENCORE Program, Creating Multiple Potential Approval Pathways

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 185

11/09/2015

Company Report

Pages: 7

Price: 24.95

Company: Histogen Inc.

Industry: Medical - Products

Record: 186

11/05/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 187

11/05/2015

Company Report

Pages: 4

3Q15 Results

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 188

10/14/2015

Company Report

Pages: 7

Price: 24.95

Company: Histogen Inc.

Industry: Medical - Products

Record: 189

09/24/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 190

09/24/2015

Daily Note

Pages: 4

Positive Impact on Portal Hypertension in Some Patients

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 191

09/22/2015

Company Report

Pages: 27

Targeting Emricasan''s Unique MOA on NASHDriven Cirrhosis; Pivotal Studies in 2016; Initiate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 75.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 192

08/06/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 193

08/06/2015

Company Report

Pages: 5

2Q15 Results

Provider: Roth Capital Partners, Inc.

Analyst: PIERCE E

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 194

05/20/2015

Industry Report

Pages: 5

Healthcare -Intercept Paves the Way

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 195

05/08/2015

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 196

05/07/2015

Daily Note

Pages: 4

Preparing for Registration Studies

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 197

03/27/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 198

03/26/2015

Company Report

Pages: 5

NASH Is Opening Up

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 199

03/17/2015

Company Report

Pages: 13

We are reinstating coverage of Conatus Pharmaceuticals with a Buy rating and $15 target price

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 50.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 200

03/17/2015

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party